IP Library Granted Patent US 11,219,609
Granted Patent B2
US 11,219,609 · App. 15/326,958 · Granted Jan 11, 2022

Aqueous formulation comprising paracetamol and ibuprofen

Inventor: Thomas Jacobsen (Windhof, LU)
Assignee: Hyloris Pharmaceuticals SA
A61K31/192A61J1/10A61J1/2093A61K9/0019A61K9/08A61K31/167A61K47/20A61K47/26A61M5/1407A61M5/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,219,609
App. No.
15/326,958
Granted
Jan 11, 2022
Kind
B2
Abstract

The present invention relates to an aqueous ibuprofen and paracetamol composition of pH 6.3-7.3 and to its use. The present invention relates to a method for preparing a combination product of ibuprofen and paracetamol. It also relates to the compositions for use as a medicament, especially for the treatment of pain and/or inflammation; especially for administration of the composition by intravenous injection.

Claims (12)

1. A process for manufacturing an aqueous composition comprising 2.8-3.2 mg/ml ibuprofen and 9.8-10.2 mg/ml paracetamol in combination, comprising the steps of:

a) providing an aqueous solvent of pH 6.0-8.0,

b) dissolving in said aqueous solvent ibuprofen and paracetamol,

c) if required adjusting the pH to 6.3-6.8,

d) thereby obtaining said aqueous composition comprising 2.8-3.2 mg/ml ibuprofen and 9.8-10.2 mg/ml paracetamol in combination at 6.3-6.8,

wherein the ibuprofen and the paracetamol remain in solution for at least 6 months at 25+/−2° C. and 40+/−5% relative humidity.

2. The process according to claim 1 , wherein said aqueous solvent has a dissolved oxygen content below 2 ppm obtainable using an aqueous solvent having a temperature between 85° C. and 99° C. and/or by bubbling an inert gas through said solvent.

3. The process according to claim 1 , wherein the composition comprises an anti-oxidant.

4. The process according to claim 1 , wherein the aqueous solvent comprises an isotonic agent.

5. The process according to claim 3 , wherein the anti-oxidant is cysteine or acetyl cysteine.

6. The process according to claim 4 , wherein the isotonic agent is mannitol.

7. The process according to claim 2 , wherein the inert gas is selected from the group consisting of nitrogen, and argon.

Assignments (3)
CHANGE OF NAME Recorded Aug 5, 2021
From: EVERBRIGHT S.A.R.L.
To: HYLORIS PHARMACEUTICALS SA
Reel/Frame 057091/0054 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 041138 FRAME: 0920. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 12, 2021
From: JACOBSON, THOMAS
To: EVERBRIGHT S.A.R.L.
Reel/Frame 056832/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2017
From: JACOBSEN, THOMAS
To: EVERBRIGHT PHARMACEUTICALS S.A.R.L.
Reel/Frame 041138/0920 →
Priority Claims (1)
WO PCT/EP2014/065544 · Jul 18, 2014 · international
Continuity (1)
Related Publication 20170209398A1 · Jul 27, 2017